Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
SOUTH SAN FRANCISCO, Calif., April 01, 2016 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. “Rusty” Williams, M.D., Ph.D., Founder, Chief Executive Officer and Chairman of the Board, will present at the 2016 Jefferies Immuno-Oncology Summit on Friday, April 8, 2016, at 11:00 A.M. Eastern Daylight Time.
A copy of the presentation will be available under the Investors section of the Company’s website at www.fiveprime.com. Five Prime will maintain archived slides on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
